Meet the team

The experience, diversity and complementarity of our team will fast-track growth, impact and profitability

Founder and Managing General Partner at Samsara BioCapital

Dr Srinivas Akkaraju

Srinivas Akkaraju is Founder and Managing General Partner at Samsara BioCapital. Previously, he was a Managing General Partner of Sofinnova Ventures. Prior to Sofinnova, Srini was a Managing Director of New Leaf Venture Partners, and prior to that, a Founding Managing Director at Panorama Capital, LLC., and prior to that, a Partner with J.P. Morgan Partners.

Before his investment career, he was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group), a biotechnology company, most recently as Senior Manager. Dr Akkaraju currently serves as a Director of Intercept Pharmaceuticals, Inc., Seattle Genetics, Versartis Inc., and Syros Pharmaceuticals.

Previously, Dr Akkaraju served as a director on the boards of ZS Pharma, Inc., Eyetech Pharmaceuticals, Inc., Synageva Biopharma Corp., aTyr Pharma, Inc., Barrier Therapeutics, Inc., and Amarin Corporation plc. Srinivas joined the Board in February 2016.

Board member

Yasmin Allen

Yasmin Allen is a non-executive director of Cochlear Limited, Chairman of its Audit Committee and a member of Cochlear’s technology committee. She is also a non-executive director of ASX Limited, member of the ASX Audit Committee and ASX Clearing and Settlement board. Yasmin is a director at Santos Limited, Chairman of Santos’ Remuneration Committee and a member of its audit committee. She is also a director of the National Portrait Gallery and Chairman of Advance, connecting innovation and IP globally.

Yasmin’s previous directorships include Insurance Australia Group Limited (IAG) where she was Chairman of IAG’s Nomination and Remuneration Committee and a member of its Audit and Risk Committee. Yasmin was also Chairman of Macquarie Global Infrastructure Funds and a National Director of the Australian Institute of Company Directors.

Prior to her directorships, Yasmin had an extensive career in investment banking, including as Vice President of Deutsche Bank, Director of ANZ Investment Bank in Sydney and Director with HSBC in London. She has a Bachelor of Commerce from Melbourne University and in 2015 was awarded their Alumni of Distinction Award.

She is a Fellow of the Australia Institute of Company Directors and a member (and former council member) of Chief Executive Women. Yasmin joined the board in August 2014.

Chief Financial Officer, George Health Enterprise

Scott Featherston

Scott is CFO and Director for Corporate Development for George Health and is an Honorary Professorial Fellow at The George Institute. Scott also has interests in education. He founded Caerus Capital, a boutique private investment firm that invests in the private education sector in Sub-Saharan Africa and he sits on the board of Luminus Education in Amman, Jordan.

Scott was formerly the Global Health Sector Leader and a Principal Investment Officer for the International Finance Corporation, the private sector arm of the World Bank Group. During his time at IFC (2005-2015), Scott led numerous transactions in the health and education sectors in Africa, MENA, South/East Asia, and Europe and founded the World Bank’s Health in Africa initiative. Scott’s early career was in engineering and finance.

He worked for a global property and project management firm before joining the finance advisory practice of a “Big 4” global consulting firm. Scott holds master’s degrees in international affairs and engineering science.

He lectured in international economics and finance at the Johns Hopkins School of Advanced International Studies in Washington DC.

Board Member

Dr. Mohit Kaushal

Dr Kaushal has had an extensive career within investing, clinical medicine/academia and public policy. Mohit is an investor/board member to numerous transformational companies including Humedica (acquired by Optum Health), Rxante (acquired by Millennium), Change Healthcare (acquired by Emdeon), Universal American (NYSE:UAM) acquired by WellCare (NYSE:WCG), Gravie, Alignment Health, Wellframe, CitiusTech and Oak Street Health.

During his time in the Obama administration, he was a member of the White House Health IT task force; a cross agency team implementing the technology aspects of the ACA and testified to Congress on the application of technology and payment reform Administration to the Medicare population.

He also built and led the first dedicated health care team at the Federal Communications Commission, where his team-initiated collaboration with the Food and Drug Administration for the regulatory streamlining of converged telecommunications, data analytics and medical devices leading to the release of the mobile medical applications guidance by the FDA. In addition, his team reformed the Rural Healthcare fund to create the Healthcare Connect Fund, which aligned the funding mechanism with wider health care payment policy and technology reform.

In addition, Dr Kaushal is an Adjunct Professor at Stanford University with a joint position within the newly created Biomedical Data Science Department and the medical school’s Clinical Excellence Research Center.

Dr Kaushal continues to be active within public policy and is a Scholar in Residence at the Duke Margolis Center for Health Policy. He was previously a Visiting Scholar at the Brookings Institution. He has also been appointed to the FDASIA Workgroup of the Health IT Policy Committee and to the National Committee on Vital and Health Statistics, advising HHS on Data Access and Use.

Dr Kaushal is an ER physician, holds an MBA from Stanford and an MD with distinction from Imperial College of Science, Technology and Medicine, London.

Executive Chairman, George Clinical

Mr Glenn Kerkhof

Glenn Kerkhof is Executive Chairman of George Clinical. Glenn has over 22 years’ experience in the contract research and drug development industry and joined George Clinical from Chiltern where he was Chief Executive Officer.

Prior to Chiltern, Glenn served as Vice President, Clinical Services for Charles River Laboratories and as Vice President, Clinical Europe for Inveresk Research. In addition, he is also non-executive director of Cell Care Australia Pty. Ltd. and Immunoglobal Pty. Ltd.

He holds a Bachelor of Commerce from Deakin University (Australia) and a Masters of Business from the University of Edinburgh (UK).

President and Chief Executive Officer, George Health

Staph Leavenworth Bakali

“We are unique business with a clear mission to provide affordable, sustainable solutions that help populations have equal access to life-saving care irrespective of their location or economic situation. This is not only socially responsible, it is the foundation of a robust business opportunity. Doing good, is good business. To me it makes complete sense.”

Mustapha “Staph” Leavenworth Bakali is President and Chief Executive Officer, and Director of George Health Enterprises. Previously Mr. Leavenworth Bakali was President & Chief Operating Officer of the Clinton Health Access Initiative (CHAI). Mr. Leavenworth Bakali has 30 years of considerable senior executive and board level experience in leading, growing, and transforming large complex and start up organisations in both developed and emerging markets in the global pharmaceutical, biotechnology and not-for profit health arenas.

Prior to CHAI, he held several senior executive and Board positions with leading pharmaceutical and biotechnology companies, including 11 years with SmithKline Beecham living and managing businesses in French West Africa, Latin America, and Europe.

Mr. Leavenworth Bakali has substantial experience and a proven track record in fundraising, negotiating and concluding a wide range of public and private sector agreements and partnerships, including cross border mergers and acquisitions. As Chief Operation Officer of Vancouver-based ID Biomedical and UK-based PowderJect Pharmaceuticals Plc, he played a significant role in transforming the two companies from R&D organizations into fully-integrated biotech companies leading to subsequent acquisitions by GlaxoSmithKline and Chiron Corporation, respectively. As Worldwide Head of Sales and Marketing of Chiron Corporation’s Vaccines Division, he played an instrumental role in negotiating the partnerships that led to the eventual development of a low-cost combination pentavalent vaccine to serve children across the world’s 70 poorest countries. Mr. Leavenworth Bakali is also the co-founder of LeapFrog Investments, the world’s first and largest investor in companies that insure underserved people in Africa and Asia.

Mr. Leavenworth Bakali serves on a number of boards as an advisor and as a non-Executive Director and Chairman. He holds a First Class Honours Degree from City of London Polytechnic and an MSc (With Distinction) from London Business School.

Principal Director and Co-Founder, The George Institute for Global Health; Chief Scientific Advisor, George Health

Professor Stephen MacMahon AO

“We founded The George Institute 20 years ago to find ways to help developing countries stem the rising tide of chronic diseases facing both young and old. Since then we have developed a range of drugs, technologies and system solutions that are highly effective in resource-poor setting. We established George Health to commercialise these and ensure their scale-up. We want to harness the power of the private sector to provide financially sustainable healthcare to the huge numbers facing early death or disability from chronic but treatable conditions.”

Co-founder of both the George Institute and George Health, Stephen is a leading authority on the treatment of non-communicable diseases as well as a recognised social entrepreneur.

He is Professor of Medicine and Oxford Martin Senior Fellow, University of Oxford; Professor of Cardiovascular Medicine, UNSW Sydney; Honorary Professor, Peking University Health Science Center; Honorary Consultant, Royal Prince Alfred Hospital (Sydney); Fellow of the Australian Academy of Sciences, Australian Academy of Health and Medical Sciences, British Academy of Medical Sciences and American College of Cardiology.

He was named EY Social Entrepreneur of the Year in 2013.

Principal Director and co-founder, The George Institute for Global Health

Professor Robyn Norton AO

Acting Executive Director, The George lnstitute for Global Health, University of Oxford Board Member, The George Institute for Global Health Board Member, George Health Enterprises Professor of Public Health, Faculty of Medicine, UNSW Sydney Professor of Global Health & Oxford Martin Senior Fellow, University of Oxford Honorary Professor, Peking University

Professor Norton has published widely and is internationally regarded for her research on the causes, prevention and management of injuries, especially road traffic and fall-related injuries, as well as the management of various critical conditions in surgical and intensive care settings.

She has had a long-standing commitment to improving women’s health and currently leads The George Institute’s research, implementation and advocacy program, which aims to improve the health of women and girls worldwide.

Chief Business Officer, George Medicines

Dr Karl Roberts

Dr Roberts has over 30 years’ experience in various commercial, general management, consultant and strategic roles in both the branded and generic pharma space and in contract manufacturing.

He has extensive global experience in strategic licensing and M&A and a proven track record in brokering deals in both established and emerging markets.

Prior to joining the George Healthcare team Dr Roberts was Global Head of Business Development at Concordia and prior to that led Cipla’s business in Western Europe for over 5 years where he was instrumental in reshaping and delivering their European growth strategy.

GHT Business Manager

Ruth Webster’s

Associate Professor Ruth Webster

After graduating from Medicine at the University of Sydney in 2001, Ruth worked in the Australian hospital system as a clinician before joining The George Institute for Global Health in 2005. She has a Masters in International Public Health as well as a PhD in Medicine and has expertise in the design, conduct and analysis of large scale clinical trials. Her unique skill mix of clinical knowledge, academic research and business management skills, has been refined through 15 years of experience in design, testing and scaleup of novel solutions to improve the management of noncommunicable diseases including electronic decision support, as well as combination pills.

Contact us


If you would like to learn more about investment opportunities in George Health, our team and our work, we would be delighted to hear from you. Please get in touch:

Twitter     Linkedin